Background And Aim: Long non-coding RNAs (lncRNAs) have been recognized as important regulators of gene expression in various human diseases. Diabetes mellitus (DM) is a long-term metabolic disorder associated with serious macro and microvascular complications. This review discusses the potential lncRNAs involved in DM-related complications such as dysfunction of pancreatic beta islets, nephropathy, retinopathy, cardiomyopathy, and peripheral neuropathy.
Methods: An extensive literature search was conducted in the Scopus database to find information from reputed biomedical articles published on lncRNAs and diabetic complications from 2014 to 2023. All review articles were collected and statistically analyzed, and the findings were summarized. In addition, the potential lncRNAs involved in DM-related complications, molecular mechanisms, and gene targets were discussed in detail.
Results: The lncRNAs ANRIL, E33, MALAT1, PVT1, Erbb4-IR, Gm4419, Gm5524, MIAT, MEG3, KNCQ1OT1, Uc.48+, BC168687, HOTAIR, and NONRATT021972 were upregulated in several diabetic complications. However, βlinc1, H19, PLUTO, MEG3, GAS5, uc.322, HOTAIR, MIAT, TUG1, CASC2, CYP4B1-PS1-001, SOX2OT, and Crnde were downregulated. Remarkably, lncRNAs MALAT1, ANRIL, MIAT, MEG3, H19, and HOTAIR were overlapping in more than one diabetic complication and were considered potential lncRNAs.
Conclusion: Several lncRNAs are identified as regulators of DM-related complications. The expression of lncRNAs is up or downregulated depending on the disease context, target genes, and regulatory partners. However, most lncRNAs target oxidative stress, inflammation, apoptosis, fibrosis, and angiogenesis pathways to mediate their protective/pathogenic mechanism of action and contribute to DM-related complications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.dsx.2023.102872 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-diabetic therapies on dental implant success in diabetes mellitus: a comprehensive review.
Front Pharmacol
December 2024
Faculty of General Medicine, Yaroslavl State Medical University, Yaroslavl, Russia.
Background And Objective: Dental implant therapy faces challenges in patients with Type 1 and Type 2 Diabetes Mellitus (T1DM and T2DM) due to adverse effects on bone metabolism and immune response. Despite advancements, diabetic patients face higher risks of peri-implantitis and compromised osseointegration. This review assesses the impact of anti-diabetic medications on implant outcomes, offering insights to bridge the gap between animal studies and clinical practice.
View Article and Find Full Text PDFRisk Factors for Cataracts in Patients with Diabetes Mellitus.
J Clin Med
November 2024
Department of Second Internal Medicine Diabetes, Nutrition, Metabolic Diseases, and Systemic Rheumatology, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Diabetes mellitus (DM) is one of the most impactful health problems worldwide. It affects ocular health in multiple ways and is one of the leading causes of vision loss. Our study aimed to evaluate the most important systemic risk factors related to the occurrence of cataracts in patients with DM.
View Article and Find Full Text PDFGuidelines and consensus: Jejunoileostomy for diabetes mellitus-surgical norms and expert consensus (2023 version).
World J Diabetes
November 2024
Department of General Surgery, The Third Medical Center of the General Hospital of the People's Liberation Army, Beijing 100039, China.
Article Synopsis
- Diabetes mellitus (DM) is a condition marked by high blood sugar levels due to inadequate insulin production, requiring patients to undergo long-term treatment with existing hypoglycemic drugs, which are often ineffective for managing the disease.
- Traditional weight loss surgeries, like gastric bypass, have strict BMI requirements and can lead to complications such as hypoglycemia and dumping syndrome, reducing their effectiveness for DM treatment.
- Jejunoileostomy is a newer surgical option showing promise for improving glucose and lipid metabolism without altering the gastrointestinal structure, resulting in fewer complications and better management of DM-related issues, supported by clinical consensus on its surgical and postoperative management.
Molecular docking and network pharmacology study on active compounds of for the treatment of diabetes mellitus.
In Silico Pharmacol
November 2024
Department of Pharmacology, NGSM Institute of Pharmaceutical SciencesNitte (Deemed to be university), Mangalore, 575018 Karnataka India.
Background: Diabetes Mellitus (DM) is a complex metabolic disorder with increasing global prevalence, necessitating the exploration of novel therapeutic strategies. , a medicinal plant with a long history of traditional use, has shown promising potential in managing DM.
Aim Of The Study: This study aims to elucidate the mechanism of action of active components of in managing DM using a combination of network pharmacology and molecular docking approaches.
Gut microbiota modulating therapy for diabetes mellitus should be individualized.
World J Diabetes
October 2024
Department of Ultrasound Medicine, Nanjing Lishui People's Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing 211200, Jiangsu Province, China.
In this editorial, we commented on two articles published online in August and September 2024 in the , which focused on modifying the gut microbiota (GM) to prevent or delay the progression of diabetes mellitus (DM) and DM-related complications. Numerous studies, many of which are animal studies, have indicated the potential role of GM in the pathogenesis of DM. However, the detailed causality and mechanisms between GM and DM have not been fully clarified.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!